Dr. Dash is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1536 N 115th St
Seattle, WA 98133Phone+1 206-668-5215Fax+1 206-668-5214
Summary
- I'm a Urologic Oncologist with expertise in laparoscopic, robotic and open surgery interested in academic positions.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Urologic Surgical Oncology, 2004 - 2007
University of MichiganResidency, Urology, 1998 - 2004- University of Michigan Health SystemInternship, Transitional Year, 1998 - 1999
University of Vermont College of MedicineClass of 1998
Certifications & Licensure
WA State Medical License 2013 - 2026
CA State Medical License 2007 - 2025
NY State Medical License 2004 - 2009
MI State Medical License 1998 - 2006- American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
- Top Doctors:LA Area Castle Connolly, 2013
- Top Doctors:San Diego Area Castle Connolly, 2013
- Join now to see all
Clinical Trials
- Chart Review of Laparoscopic Radical Cystectomy Start of enrollment: 2005 Dec 01
- Incidence of Antibiotic Resistant E.Coli in Patients Undergoing Repeat Prostate Biopsy Start of enrollment: 2008 Oct 01
- S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsLong-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.Lisa F Newcomb, Jeannette M Schenk, Yingye Zheng, Menghan Liu, Kehao Zhu
JAMA. 2024-06-25 - The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance.Jonathan L Wright, Jeannette M Schenk, Roman Gulati, Sarah J Beatty, Matthew VanDoren
Cancer. 2024-06-15 - 3 citationsA Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer.Dimitrios Makrakis, Jonathan L Wright, Martine P Roudier, Jose Garcia, Funda Vakar-Lopez
Clinical Genitourinary Cancer. 2023-04-01
Journal Articles
- Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk StabilityMatthew R Cooperberg, Atreya Dash, JAMA Oncology
Authored Content
- Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk StabilityAugust 2020
- Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk StabilityAugust 2020
- Does the Diagnosis of Bladder Cancer Lead to Higher Rates of Smoking Cessation? Findings from the Medicare Health Outcomes SurveyMarch 2019
Press Mentions
Comorbidities Should Be Factor in Prostate Biopsy Choice, UCI Study FindsFebruary 10th, 2016
Professional Memberships
- Member
- Member
- Society of Urologic OncologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
